# STARCOIN GROUP LIMITED
# 星 太 鏈 集 團 有 限 公 司

*(Formerly known as Innovative Pharmaceutical Biotech Limited 領航醫藥及生物科技有限公司)*
*(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)*
**(Stock Code: 399)**

## QUARTERLY UPDATES ON PROGRESS OF RESUMPTION AND CONTINUED SUSPENSION OF TRADING

This announcement is made by Starcoin Group Limited (formerly known as Innovative Pharmaceutical Biotech Limited) ("**Company**", together with its subsidiaries, "**Group**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities ("**Listing Rules**") on The Stock Exchange of Hong Kong Limited ("**Stock Exchange**") and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong) ("**SFO**").

References are made to the announcement of the Company dated 5 May 2026 and 1 June 2026 in relation to the outcome of the application for the judicial review and the interim injunction against the decision of the listing decision of the Listing Review Committee and resumption guidance issued by Stock Exchange (collectively the "**Announcements**"). Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Announcements.

## UPDATE ON BUSINESS OPERATIONS

The Company is an investment holding company. The Group is principally engaged in the trading of beauty and healthcare products and research and development of oral insulin. Since the suspension of trading in the shares of the Company ("**Shares**") on 6 May 2026 and up to the date of this announcement, the Group has been continued its business operations in all material respects.

## RESUMPTION GUIDANCE

On 28 May, 2026, the Company received a letter from the Stock Exchange setting out the following guidance ("**Resumption Guidance**") for the resumption of trading in the Shares:

(i) demonstrate the Company's compliance with Rule 13.24 of the Listing Rules; and

(ii) inform the market of all material information for the Company's shareholders and investors to appraise the Company's position.

The Company must meet all Resumption Guidance, remedy the issues causing its trading suspension and fully comply with the Listing Rules to the Stock Exchange's satisfaction before trading in its securities is allowed to resume. For this purpose, the Company has the primary responsibility to devise its action plan for resumption. Whilst the Company may seek guidance from the Stock Exchange on its resumption plan, its resumption plan is not subject to the Stock Exchange's prior approval before implementation. The Stock Exchange also indicated that it may further modify or supplement the Resumption Guidance if the Company's situation changes.

## UPDATE ON RESUMPTION PLAN

The Company is currently assessing the implications of Rule 13.24 of the Listing Rules. The Company has also engaged Donvex Capital Limited as the financial adviser to assist with the resumption process and to formulate the necessary measures required for compliance with the Listing Rules. In addition, the Company has been actively seeking acquisition and cooperation opportunities, continuing to explore ways to optimise its trading of beauty and healthcare products, while expanding and diversifying its related businesses. The aim is to develop a comprehensive and feasible resumption plan that addresses all matters set out in the Resumption Guidance.

Further announcement(s) will be made by the Company as and when appropriate and in accordance with the requirements of the Listing Rules to keep its Shareholders and potential investors informed of the latest progress in complying with the Resumption Guidance.

## CONTINUED SUSPENSION OF TRADING

At the request of the Company, the trading in the shares of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on Wednesday, 6 May 2026 and will remain suspended until further notice.

**Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board
**Starcoin Group Limited**
**Yeung Yung**
*Chairman*

Hong Kong, 5 August 2026

*As at the date of this announcement, the Board comprises, Dr. Yeung Yung (Chairman and executive Director), Mr. Gao Yuan Xing (executive Director), Mr. Tang Rong (executive Director), Ms. Qi Shujuan (executive Director), Dr. Long Fan (executive Director), Dr. Wu Ming (executive Director), Mr. Zhang Shen (executive Director), Mr. Zhang Yi (non-executive Director), Ms. Chen Weijun (independent non-executive Director), Mr. Wang Rongliang (independent non-executive Director), Mr. Chen Jinzhong (independent non-executive Director), Dr. Xia Tingkang, Tim (independent non-executive Director) and Ms. Sun Sizheng (independent non-executive Director).*

*Please also refer to the published version of this announcement on the Company's website: starcoingroup.com.*